Eli Lilly has teamed up with Strides Arcolab in India to market the latter's generic cancer drugs in emerging markets.
Under the terms of the deal, Lilly will register and market up to an initial 10 medicines manufactured by Strides' arm Agila Specialities in various emerging markets, the firms said.
Lilly also holds the right to expand the agreement with additional branded generic oncology products in the future.
The move builds on Lilly's recent investment in a branded generics platform in China earlier this year, and helps the firm "expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets", said Jacques Tapiero, Lilly Senior Vice President and President of its emerging markets division.
Further details of the deal - including the financial aspects - were not revealed.